Chicago, IL—“Difficult” atrial fibrillation (AF), for which standard ratecontrol therapy or standard rhythmcontrol therapy has not been effective, or AF in the setting of sinus node or other conduction disease, has been shown to sometimes benefit from nonstandard or combination-drug treatment, according to James A. Reiffel, MD, Professor of Clinical Medicine, Columbia University Medical Center, New York City.
Cardiac Resynchronization Therapy Still Challenging in Patients with Atrial Fibrillation and Heart Failure
Chicago, IL—Cardiac resynchronization therapy (CRT) in the setting of atrial fibrillation (AF) and heart failure (HF) has clear challenges, and the evidence is mixed about its benefit.
Chicago, IL—In patients with atrial fibrillation (AF) who underwent catheter ablation, the new anticoagulant dabigatran (Pradaxa), an oral direct thrombin inhibitor, was found to effectively prevent thromboembolic events in a small prospective study presented by Charlotte Eitel, MD, Department of Electrophysiology, Heart Center Leipzig, Germany, at the 2012 American College of Cardiology meeting. Patients with AF are known to be at increased risk for thromboembolic events.
Comparative Effectiveness Analysis of Antithrombotics in Older Patients with Post-ACS Atrial Fibrillation
Chicago, IL—Similar outcomes were found with 2 different antithrombotic strategies in a comparative effec - tiveness study in patients with atrial fibrillation (AF) after a non–ST-segment elevation myocardial infarction (NSTEMI). But a trend toward more bleeding with intensified treatment was found.
Chicago, IL—The new oral anticoagulants— the factor Xa inhibitors rivaroxaban (Xarelto) and apixaban (Eliquis), and the direct thrombin inhibitor dabigatran (Pradaxa)—are superior to warfarin (Coumadin) in preventing stroke and systemic embolism in patients with atrial fibrillation (AF), according to a review/meta-analysis conducted by Mark J. Eisenberg, MD, MPH, Associate Professor of Medicine, Director of McGill Cardiology Fellowship Programs at McGill University, Montreal, Quebec, Canada, and colleagues at the 2012 American College of Cardiology meeting.
Results 1 - 5 of 5